Dr Reddy's Signs Licensing Agreement with Gilead for Once-Yearly HIV Prevention Drug
Dr Reddy's Laboratories has signed a royalty-free, non-exclusive licensing agreement with Gilead Sciences to manufacture and supply investigational once-yearly lenacapavir for HIV prevention across 120 countries, including India. This builds on a prior pact for twice-yearly lenacapavir, which is approved by US and European regulators and recommended by WHO. The once-yearly formulation is undergoing Phase 3 trials and remains unapproved, with safety and efficacy yet to be established.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 44/100.
Outlets measured: economictimes, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 17 Sept, 08:16 am. Other outlets followed.